We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.97 | 0.74% | 132.86 | 133.62 | 131.00 | 131.45 | 2,411,864 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Shares of Dicerna Pharmaceuticals Inc. (DRNA) rose nearly 18% on Monday after the biopharmaceutical company said it would collaborate with Novo Nordisk A/S (NVO) to develop therapies for liver-related cardio-metabolic diseases.
Dicerna will a $175 million upfront payment and a $50 million equity investment from Novo, and it is eligible for up to $357.5 million in milestone payments per target under the deal.
Dicerna late last month announced a similar deal with Roche Holding AG (ROG.EB) focused on chronic hepatitis B virus infection that is worth up to $1.67 billion in upfront and milestone payments to Dicerna.
Analysts at SVB Leerink, which have an "outperform" rating on Dicerna shares, said the deals further validate the company's GalXC-RNAi platform and "superb execution."
Dicerna shares were recently up 17.9%, to $22.75.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 18, 2019 10:54 ET (15:54 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
